Cibc World Markets Corp Nektar Therapeutics Transaction History

Cibc World Markets Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 10, 2021	SELL	$16.52 - $20.4 $323,164 - $399,064	-19,562 Closed	0 $0
Q1 2021 May 07, 2021	BUY	$16.56 - $25.46 $323,946 - $498,048	19,562 New	19,562 $391,000
Q4 2019 Feb 13, 2020	SELL	$15.87 - $23.12 $1 Million - $1.46 Million	-63,036 Closed	0 $0
Q3 2019 Nov 12, 2019	BUY	$16.91 - $36.27 $392,447 - $841,754	23,208 Added 58.27%	63,036 $1.15 Million
Q2 2019 Aug 13, 2019	SELL	$31.0 - $36.3 $57,319 - $67,118	-1,849 Reduced 4.44%	39,828 $1.42 Million
Q1 2019 May 14, 2019	SELL	$31.58 - $46.35 $456,646 - $670,221	-14,460 Reduced 25.76%	41,677 $1.4 Million
Q4 2018 Feb 13, 2019	BUY	$30.43 - $56.65 $257,072 - $478,579	8,448 Added 17.71%	56,137 $1.85 Million
Q3 2018 Nov 13, 2018	BUY	$46.46 - $68.49 $552,037 - $813,798	11,882 Added 33.18%	47,689 $2.91 Million
Q2 2018 Aug 13, 2018	BUY	$46.25 - $104.45 $276,390 - $624,193	5,976 Added 20.03%	35,807 $1.75 Million
Q1 2018 May 11, 2018	BUY	$57.4 - $108.44 $1.71 Million - $3.23 Million	29,831 New	29,831 $3.17 Million

147

139M

32.6K

14.1K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $193M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Cibc World Markets Corp, based on Form 13F filings with the SEC.

Stay updated on Cibc World Markets Corp with notifications on news.